Eton Pharmaceuticals, Inc.
NASDAQ:ETONBiotechnology
-$0.46 today
- Market cap
- $1.79B
- Beta
- 0.89
- P/E (TTM)
- -597.6
- EPS (TTM)
- -$0.05
Volume 0.48M
Average 0.43M
ETON Income Tax Expense
Income taxes recognized for the period, including current and deferred tax.
Eton Pharmaceuticals, Inc.NASDAQ: ETON
Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026
Income tax expense declines year over year
Q1 FY2026 income tax expense of $20K fell 73.0% year over year, ahead of the -112.4% change in trailing-twelve-month income tax expense.
Context
- Income tax expense amounted to 0.1% of revenue in FY2025, unchanged from a year earlier.
- Income tax expense increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -73.0% holds above the trailing-twelve-month pace of -112.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Income Tax Expense history
USD · from the income statement
- Latest · FY2025
- 43K USD
- Year-over-year change
- +186.7%
| Period | Period end | Income Tax Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 43K | +186.7% |
| FY2024 | 2024-12-31 | 15K | -93.9% |
| FY2023 | 2023-12-31 | 247K | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Income Tax Expense vs competitors
How ETON compares with its peers on the latest reported figures
- ETON's LTM Mar 2026 income tax expense of -$11K is the 9th highest of the 10 companies compared; the peer median is $106K.
- Its year-over-year change of -112.4% is the lowest of 8, against a peer median of -27.6%.
- Income tax expense amounts to 0.0% of revenue for ETON, versus a peer median of 0.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $9.18M | -44.8% | — | 7.5% | |
| LTM Mar 2026 | $7.7M | -27.6% | +98.9% | 2.1% | |
| LTM Sep 2026 | $6.49M | +129940.0% | +46.7% | 1.0% | |
| LTM Mar 2026 | $3.82M | +55.8% | -11.1% | 0.6% | |
| LTM Mar 2026 | $106K | -71.0% | — | 0.2% | |
| LTM Mar 2026 | $15K | -48.3% | +0.0% | — | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | -$11K | -112.4% | — | 0.0% | |
| LTM Sep 2026 | -$187K | +92.1% | -56.0% | 0.0% | |
| Peer median (excluding ETON) | $106K | -27.6% | +0.0% | 0.6% | |
Competitors are the stored peer set for ETON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 21.83M | 21.25M | 31.64M | 39.01M | 79.95M |
| Cost of Revenue | 2.62M | 6.93M | 10.58M | 15.6M | 37.21M |
| Gross Profit | 19.21M | 14.32M | 21.06M | 23.41M | 42.74M |
| Gross Margin | 88.0% | 67.4% | 66.6% | 60.0% | 53.5% |
| Research & Development | 6.24M | 4M | 3.32M | 3.26M | 7.77M |
| Selling, General & Admin | 14.47M | 18.58M | 18.93M | 22.75M | 35.82M |
| Operating Expenses | 20.7M | 22.58M | 22.25M | 26.01M | 42.67M |
| Depreciation & Amortization | 462K | 1.77M | 901K | 1.15M | 4.04M |
| EBITDA | (1.49M) | (7.25M) | 212K | (657K) | 4.27M |
| EBITDA Margin | -6.8% | -34.1% | 0.7% | -1.7% | 5.3% |
| Operating Income | (1.5M) | (8.26M) | (1.19M) | (2.6M) | 72K |
| Operating Margin | -6.8% | -38.9% | -3.8% | -6.7% | 0.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.04M | 955K | 1.06M | 2.01M | 4.78M |
| Other Income / Expenses | (460K) | (761K) | 503K | (1.21M) | (4.63M) |
| Income Before Tax | (1.96M) | (9.02M) | (689K) | (3.81M) | (4.56M) |
| Pre-Tax Margin | -9.0% | -42.4% | -2.2% | -9.8% | -5.7% |
| Income Tax Expense | 0 | 0 | 247K | 15K | 43K |
| Net Income | (1.96M) | (9.02M) | (936K) | (3.82M) | (4.6M) |
| Net Margin | -9.0% | -42.4% | -3.0% | -9.8% | -5.8% |
| EPS (Basic) | (0.08) | (0.36) | (0.04) | (0.15) | (0.17) |
| EPS (Diluted) | (0.08) | (0.36) | (0.04) | (0.15) | (0.17) |
| Weighted Avg Shares | 25.21M | 25.15M | 25.65M | 25.9M | 26.91M |
| Weighted Avg Shares (Diluted) | 25.21M | 25.15M | 25.65M | 25.9M | 26.91M |
Eton Pharmaceuticals, Inc.
NASDAQ:ETON
Intrinsic Alpha fair value
Locked
Current Price
$61.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.